Consonance Capital Management LP Tcr2 Therapeutics Inc. Transaction History

Consonance Capital Management LP

  • $7.28 Million
  • Q3 2022

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021
SELL
$20.38 - $34.07 $11.9 Million - $19.9 Million
-584,885 Closed
0 $0
Q4 2020

Feb 16, 2021
SELL
$19.0 - $32.63 $17.6 Million - $30.2 Million
-924,934 Reduced 61.26%
584,885 $71.3 Million
Q3 2020

Nov 16, 2020
BUY
$13.1 - $20.69 $19.8 Million - $31.2 Million
1,509,819 New
1,509,819 $30.7 Million

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Consonance Capital Management LP Portfolio

Follow Consonance Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Consonance Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email